PERKINELMER INC Stock Price, News & Analysis

PerkinElmer, Inc. (NYSE: PKI) has released its 2021 Corporate Social Responsibility (CSR) Report, detailing its progress in environmental, social, and governance (ESG) initiatives. The report highlights a 8.5% reduction in Scope 1 and 2 emissions, a 15% decrease in hazardous waste, and increased female representation in leadership roles to 31%. Four new commitments were announced, targeting carbon neutrality by 2040, waste reduction by 2025, and enhancing female leadership. The company aims to maintain transparency in its ESG goals under SASB guidelines.

The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, set to be paid on February 11, 2022. Shareholders on record by January 21, 2022 will receive this dividend. In 2020, the company reported revenues of approximately $3.8 billion and employs about 15,000 people worldwide. PerkinElmer is a key player in the S&P 500 Index, serving customers in 190 countries, and is focused on innovating for a healthier world.

PerkinElmer (NYSE: PKI) and Honeycomb Biotechnologies have launched the innovative HIVE^TM scRNAseq Solution, designed for single-cell isolation and analysis. This portable device allows the capture, storage, and RNA sequencing of fragile cell types without the need for specialized equipment, enhancing research opportunities. The HIVE solution maintains sample integrity, improving workflow efficiency for multi-site studies. This technology aims to drive advancements in diagnostics and therapeutic development, particularly for academic collaborations and clinical trials.

PerkinElmer, Inc. (NYSE: PKI) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results, featuring CEO Prahlad Singh and CFO Jamey Mock. Investors can access a live audio webcast via the company’s website. A replay of the call will be available after 7:00 p.m. ET on the same day. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and aims to innovate for a healthier world.

PerkinElmer, NYSE:PKI, has received Emergency Use Authorization (EUA) from the FDA for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1. This test allows labs to simultaneously detect and differentiate between SARS-CoV-2, influenza A, influenza B, and RSV from respiratory samples. The test aims to streamline testing during the flu season, helping to alleviate confusion from similar symptoms. PerkinElmer's existing CE marking for this test in over 30 countries is also noted. The company reported revenues of approximately $3.8 billion in 2020.

PerkinElmer has received Emergency Use Authorization (EUA) from the U.S. FDA for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies against the SARS-CoV-2 S1 antigen in human serum and plasma. It is designed for use by CLIA-certified laboratories and plays a critical role in vaccine development and research on immunity. The assay can be used manually or on various ELISA platforms, enhancing laboratory capabilities in understanding COVID-19 immunity.

PerkinElmer, Inc. (NYSE: PKI) has successfully completed its acquisition of BioLegend for approximately $5.25 billion. This strategic move represents the largest acquisition in PerkinElmer's history, expanding its life science offerings into high-growth sectors such as cytometry and proteogenomics. BioLegend is projected to enhance PerkinElmer's revenue by $380 million and contribute $0.30 to adjusted earnings per share in fiscal year 2022. The integration aims to bolster innovation in therapeutic discovery and improve the overall reagents portfolio.

PerkinElmer (NYSE: PKI) announced the pricing of a total of $2.3 billion in senior notes, with maturities ranging from 2023 to 2031. This includes $500 million of 0.550% notes due 2023, $800 million of 0.850% notes due 2024, $500 million of 1.900% notes due 2028, and $500 million of 2.250% notes due 2031. The proceeds are intended to partially finance the acquisition of BioLegend, Inc. The offering is set to close on September 10, 2021.

PerkinElmer, Inc. (NYSE: PKI) will present at the Baird Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. During the virtual event, Steve Willoughby, Vice President of Investor Relations, will discuss the company's strategic priorities. A live audio webcast can be accessed in the Investors section of the company's website, with a replay available for 90 days post-event. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and has over 14,000 employees worldwide.